Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From the bleach that powers hospital disinfection to Hidden Valley salad dressing on kitchen tables, Clorox’s portfolio touches nearly every room of the home—and that breadth shows up in its SEC paperwork. The 10-K alone tracks raw-material inflation on sodium hypochlorite, charcoal volumes at Kingsford, and plastic-reduction targets across Brita and Glad. If you’ve ever searched Google for “Clorox SEC filings explained simply” or wondered where to locate a “Clorox insider trading Form 4 transactions” alert, you’re in the right place.
Stock Titan’s AI decodes each release the moment it hits EDGAR. Our real-time engine flags “Clorox Form 4 insider transactions real-time,” pulls margin commentary from every “Clorox quarterly earnings report 10-Q filing,” and distills risk-factor changes so you can grasp them in minutes. Need to understand the ESG footnotes? Click the “Clorox annual report 10-K simplified” summary. Curious about board pay? The platform links directly to the “Clorox proxy statement executive compensation” tables and highlights year-over-year shifts.
Investors use these insights to monitor bleach demand during flu season, compare segment profits between Household and Lifestyle units, and track “Clorox 8-K material events explained”—from factory outages to strategic divestitures. Whether you’re screening “Clorox earnings report filing analysis” for revenue trends or verifying “Clorox executive stock transactions Form 4” before making a move, Stock Titan equips you with AI-powered summaries, real-time filing updates, and comprehensive coverage of every form—saving you hours of document review.
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 1,441 shares of common stock via restricted stock units at an attributable price of $124.85 per share. After the transaction Ms. Peck beneficially owned 5,821 shares directly and 100 shares indirectly through a trust of a parent. The restricted stock units vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Stacey Grier, EVP & Executive Chief of Staff at The Clorox Company (CLX), reported an acquisition of 3,364 restricted stock units on 09/16/2025. The Form 4 shows the units were recorded at a price of $124.85 and, after the transaction, Ms. Grier beneficially owned 23,190 shares. The restricted stock units vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The filing was signed by an attorney-in-fact on 09/18/2025.
Angela C. Hilt, Executive Vice President and Chief Legal Officer of The Clorox Company (CLX), reported an acquisition of 7,048 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the reported transaction she beneficially owns 26,881 shares directly. The filing also discloses indirect ownership of 609.663 shares held via the company 401(k) plan. The acquired shares are described as Restricted Stock Units that will vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029.
Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.
Chris T. Hyder, EVP—Group President, Health & Hygiene at The Clorox Company (CLX), reported an equity award conversion on 09/16/2025. The filing shows the acquisition of 7,208 shares of Clorox common stock at an indicated price of $124.85 per share, bringing his total beneficial ownership to 29,325 shares. The shares arise from Restricted Stock Units that vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025. This disclosure records an insider share increase tied to compensation rather than an open-market purchase.
Nina Barton, Executive Vice President and Group President - Care & Connections at The Clorox Company (CLX), reported an acquisition on 09/16/2025 of 7,208 shares of Clorox common stock at a reported price of $124.85 per share, increasing her beneficial ownership to 28,496 shares. The filing indicates these shares are restricted stock units that will vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The Form 4 was submitted by attorney-in-fact Jinho Joo on 09/18/2025.
Eric H. Reynolds, EVP and Chief Operating Officer of The Clorox Company (CLX), reported an acquisition of company common stock on 09/16/2025. The Form 4 shows an acquisition of 9,611 shares at a price of $124.85 per share, bringing his beneficial ownership to 63,832 shares following the transaction. The filing also discloses Restricted Stock Units that vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The form was signed by an attorney-in-fact on 09/18/2025.
Luc Bellet, EVP and Chief Financial Officer of The Clorox Company (CLX), reported an open-market purchase of 7,368 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the purchase, the filing shows Mr. Bellet beneficially owned 19,546 shares. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
The filing also discloses restricted stock units that will vest in four equal installments on October 5, 2026, October 5, 2027, October 5, 2028, and October 5, 2029. No derivative transactions, dispositions, or additional cash- or price-related terms beyond the reported purchase price are included in the document.
Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Eric H. Reynolds, Executive Vice President and Chief Operating Officer of The Clorox Company (CLX), reported transactions dated 09/04/2025. The filing shows an exercise of stock options (derivative) to acquire 15,210 shares at an exercise/conversion price of $111.60, and a related non-derivative acquisition of 15,210 shares (reported at $111.60). The report also discloses a sale of 15,041 shares at a weighted average price of $123.7848 (trade prices ranged $123.731–$123.84). Following these transactions the reporting person is shown as beneficially owning 69,262 shares after the acquisition and 54,221 shares after the sale. The form is signed by an attorney-in-fact on 09/08/2025.
FAQ
What is the current stock price of Clorox Co Del (CLX)?
What is the market cap of Clorox Co Del (CLX)?
